| US 11,814,368 B2 | ||
| Triazine derivatives having virus replication inhibitory activity and pharmaceutical composition comprising the same | ||
| Yuki Tachibana, Osaka (JP); Shota Uehara, Osaka (JP); Yuto Unoh, Osaka (JP); Kenji Nakahara, Osaka (JP); Yoshiyuki Taoda, Osaka (JP); Yukiko Yamatsu, Osaka (JP); Shigeru Ando, Osaka (JP); and Michihito Sasaki, Hokkaido (JP) | ||
| Assigned to SHIONOGI & CO., LTD., Osaka (JP)NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, Hokkaido (JP) | ||
| Filed by Shionogi & Co., Ltd., Osaka (JP); and NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, Hokkaido (JP) | ||
| Filed on Apr. 29, 2022, as Appl. No. 17/733,366. | ||
| Application 17/733,366 is a continuation of application No. PCT/JP2022/006496, filed on Feb. 17, 2022. | ||
| Claims priority of application No. 2021-068672 (JP), filed on Apr. 14, 2021; application No. 2021-105802 (JP), filed on Jun. 25, 2021; and application No. 2021-153819 (JP), filed on Sep. 22, 2021. | ||
| Prior Publication US 2023/0212154 A1, Jul. 6, 2023 | ||
| This patent is subject to a terminal disclaimer. | ||
| Int. Cl. C07D 403/14 (2006.01); A61P 31/14 (2006.01); A61K 31/53 (2006.01); A61K 47/54 (2017.01) | ||
| CPC C07D 403/14 (2013.01) [A61K 31/53 (2013.01); A61K 47/542 (2017.08); A61P 31/14 (2018.01)] | 15 Claims |
|
1. A compound represented by the following Formula:
 or a pharmaceutically acceptable salt thereof. |